trending Market Intelligence /marketintelligence/en/news-insights/trending/sdhztqchk7l2_5wwxqco6w2 content esgSubNav
In This List

GSK lung disease drug rejected by US FDA

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


GSK lung disease drug rejected by US FDA

U.K.-based GlaxoSmithKline PLC said the U.S. Food and Drug Administration rejected Nucala as an add-on treatment for patients with a certain type of lung disease.

The drugmaker is seeking approval for Nucala, or mepolizumab, as an add-on to corticosteroid-based maintenance therapy to lessen the severity of symptoms of chronic obstructive pulmonary disease. The agency asked for more clinical data.

GSK plans to work with the U.S. regulator to determine next steps for the application.

The rejection came weeks after the U.S. FDA's Pulmonary Allergy Drugs Advisory Committee questioned the effectiveness of Nucala and voted against its approval, questioning the drug's risk-benefit profile.

Nucala is already approved for patients with severe asthma in the U.S.